1. Global Initiative for Asthma (GINA). Accessed date: 2025 February 23. Available from: http://www.ginasthma.org.
2.
Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J 2019; 12: 100007.
3.
Niemiec A, Branicka O, Rymarczyk B, et al. Biological treatment options for eosinophilic asthma, with consideration of markers of eosinophilic inflammation as predictors of treatment efficacy. Pol J Allergol 2024; 11: 163-72.
4.
Celik GE, Aydin O, Gokmen D, et al. Picturing asthma in Turkey: results from the Turkish adult asthma registry. J Asthma 2023; 60: 1973-86.
5.
Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol 2022; 150: 1097-105.e12.
6.
Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1043-57.
7.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1023-42.
8.
Cakmak ME, Öztop N, Yeğit OO, et al. Evaluation of the clinical features and laboratory data of patients with severe eosinophilic asthma classified as super-responders, partial responders, or nonresponders to mepolizumab treatment: a real-life study. Int Arch Allergy Immunol 2023; 184: 736-43.
9.
Cakmak ME, Öztop N, Yeğit OO, et al. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study. J Asthma 2023; 60: 1862-8.
10.
Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol 2022; 42: 1473-507.
11.
Maglione PJ. Chronic lung disease in primary antibody deficiency: diagnosis and management. Immunol Allergy Clin North Am 2020; 40: 437-59.
12.
Kaya SB, Çakmak ME, Bostan ÖC, et al. Respiratory system evaluation of adult primary immunodeficiency patients: a tertiary care center experience. Postep Hig Med Dosw 2025; 79: 1-6.
13.
Lee SH, Ban GY, Kim SC, et al. Association between primary immunodeficiency and asthma exacerbation in adult asthmatics. Korean J Intern Med 2020; 35: 449-56.
14.
Tiotiu A, Salvator H, Jaussaud R, et al. Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. Allergol Int 2020; 69: 215-22.
15.
Kılınç M, Çölkesen F, Aykan FS, et al. Evaluation of primary immunodeficiency awareness of physicians in Türkiye. Pol J Allergol 2025; 12: 29-36.
16.
Adatia A, Allen CJ, Wald J, et al. Benralizumab for prednisone-dependent eosinophilic asthma associated with novel STAT3 loss of function mutation. Chest 2021; 159: 181-4.
17.
Lan J, Zhang Y, Song M, et al. Omalizumab for STAT3 hyper-IgE syndromes in adulthood: a case report and literature review. Front Med 2022; 9: 835257.
18.
Tiotiu A, De Meulder B, Vaillant P, et al. Suboptimal response to biologics in severe asthma-a marker of humoral immunodeficiencies. J Allergy Clin Immunol Pract 2024; 12: 1840-9.
19.
Gomes N, Miranda J, Lopes S, et al. Omalizumab in the treatment of hyper-IgE syndrome: 2 case reports. J Investig Allergol Clin Immunol 2020; 30: 191-2.
20.
Jesenak M, Zelieskova M, Repko M, et al. Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome. Cent Eur J Immunol 2020; 45: 361-3.
21.
Brodska P, Panzner P, Sedlacek D, et al. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection. Dermatol Ther 2020; 33: e14159.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
